An efficacy study of a single dose treatment of PRO-513 [diclofenac potassium; ProEthic Pharmaceuticals] for subjects suffering a migraine attack

Trial Profile

An efficacy study of a single dose treatment of PRO-513 [diclofenac potassium; ProEthic Pharmaceuticals] for subjects suffering a migraine attack

Completed
Phase of Trial: Phase III

Latest Information Update: 13 May 2015

At a glance

  • Drugs Diclofenac potassium (Primary)
  • Indications Migraine with aura; Migraine without aura
  • Focus Registrational; Therapeutic Use
  • Acronyms IMPACT
  • Sponsors Kowa Pharmaceuticals America
  • Most Recent Events

    • 13 Apr 2011 Results presented at the 63rd Annual Meeting of the American Academy of Neurology.
    • 26 Oct 2010 Results of this and another pivotal safety and efficacy study of CAMBIA will be presented at the 4th World Congress on Controversies in Neurology Conference (CONy), according to a Nautilus Neurosciences media release.
    • 08 Apr 2010 Secondary endpoint 'Sustained response' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top